Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lung Neoplasms 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Hairy Cell 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Ependymoma 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1

Interventions

pembrolizumab 189Cisplatin 47Paclitaxel 45Carboplatin 44lenvatinib 31Docetaxel 23Pemetrexed 21Fluorouracil 20Capecitabine 17Gemcitabine 15Oxaliplatin 14Saline Solution 13Albumin-Bound Paclitaxel 11130-nm albumin-bound paclitaxel 10epacadostat 9Leucovorin 9Cetuximab 9olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6enzalutamide 5durvalumab 5belzutifan 5Nivolumab 5Dexamethasone 5Surgical Procedures, Operative 4Radiotherapy 4trifluridine tipiracil drug combination 3spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Histamine Antagonists × Clear all
NCT06788912 2026-06-01

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡